Pemafibrate has a novel mechanism of action to lower LDL-C and ApoB in patients with higher LDL-C levels: Insights from a phase 2 exploratory clinical pharmacology crossover study
Event: ESC Congress 2023
Topic: Lipid-Lowering Agents
Session: Hypertriglyceridemia treatment: CEPT, icosapent ethyl, and fibrates
